Vall d'Hebron University Hospital at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Vall d'Hebron University Hospital takes part in 22 sessions at ESMO 2026 in Madrid. Its program centres on precision treatment for lung and colorectal cancer, including ROS1-rearranged and HER2-mutant non-small cell lung cancer and BRAF-mutant colorectal cancer. Other sessions cover breast cancer risk assessment and prevention, thyroid and neuroendocrine tumours, second-line kidney cancer treatment and chronic lymphocytic leukaemia.
| Organization | ESMO 2026 Attendance |
|---|---|
Vall d'Hebron University Hospital Barcelona, Spain | |
Public university hospital in Barcelona, Spain, whose campus includes a dedicated oncology research institute, the Vall d'Hebron Institute of Oncology. | Satellite Fri Oct 23 09:45–11:15 Satellite Fri Oct 23 10:30–10:50 Building on Established IO to Reach New Heights Lung & thoracic cancers Satellite Fri Oct 23 10:43–10:58 Emerging Second-Line Treatment Strategies Genitourinary cancers Satellite Fri Oct 23 10:50–11:10 Keeping the Patient in the Center Lung & thoracic cancers Talk Fri Oct 23 13:30 Abstract Fri Oct 23 14:07–14:12 699RO - Dose escalation of Debio 0123 (zedoresertib) plus temozolomide (TMZ) in patients (pts) with recurrent or progressive glioblastoma (GBM) Sarcoma, CNS, head & neck and rare cancers Talk Fri Oct 23 16:15–16:35 Diagnostics and risk stratification of newly diagnosed chronic lymphocytic leukemia Haematological malignancies Abstract Fri Oct 23 16:30–16:35 Abstract Fri Oct 23 17:15–17:20 4212RO - Molecular determinants of cabozantinib efficacy in Advanced Radioiodine- refractory (RAIR) Differentiated Thyroid Cancer (DTC): The GETNE-CABOTHYROID Trial Sarcoma, CNS, head & neck and rare cancers Talk Sat Oct 24 08:30–08:45 Targeting the RAS/RAF pathway in CRC: Where do we stand and future perspectives Gastrointestinal cancers Satellite Sat Oct 24 13:00–14:30 Satellite Sat Oct 24 13:00–13:05 Welcome & Introductions Breast cancer Satellite Sat Oct 24 13:20–13:40 Anti-EGFR and BRAF inhibitor combinations: The cutting edge of treatment for BRAF mt mCRC Gastrointestinal cancers Satellite Sat Oct 24 13:55–14:25 Exploring the evolving 1L HER2+ BC landscape Breast cancer Satellite Sat Oct 24 14:25–14:30 Close Breast cancer Chair Sat Oct 24 14:45–16:15 Rare GU cancers Genitourinary cancers Talk Sat Oct 24 15:30–15:45 Papillary RCC Genitourinary cancers Talk Sun Oct 25 08:30–08:50 Talk Sun Oct 25 09:00 Satellite Sun Oct 25 13:00–14:30 Pierre Fabre Laboratories - BRAFV600E-mutant mCRC: Precision medicine in practice Gastrointestinal cancersBiomarkers & precision oncology Satellite Sun Oct 25 13:00–13:03 Welcome and introductions Gastrointestinal cancersBiomarkers & precision oncology Satellite Sun Oct 25 13:03–13:10 The CRC mutational landscape Gastrointestinal cancersBiomarkers & precision oncology Satellite Sun Oct 25 13:55–14:25 From the clinic: Applying precision medicine in practice Gastrointestinal cancersBiomarkers & precision oncology Satellite Sun Oct 25 14:25–14:30 Future directions and close Gastrointestinal cancersBiomarkers & precision oncology Chair Sun Oct 25 14:45–16:00 LARC: The essential role of multidisciplinary management of locally advanced rectal cancer Gastrointestinal cancers Talk Sun Oct 25 14:45–15:05 Presentation by Expert Lung & thoracic cancers Talk Sun Oct 25 14:45–14:50 Presentation of case/condition Gastrointestinal cancers Abstract Sun Oct 25 15:55–16:05 Talk Sun Oct 25 16:30–16:45 Chair Sun Oct 25 16:30–18:00 Talk Sun Oct 25 16:55–17:20 Chair Sun Oct 25 18:30–20:00 Talk Sun Oct 25 18:30–18:45 Introduction: Presentation of a clinical case of a patient with ROS1-rearranged advanced Lung & thoracic cancers Abstract Mon Oct 26 11:07–11:17 Abstract Mon Oct 26 11:17–11:27 Talk Mon Oct 26 15:45–16:05 Satellite Mon Oct 26 19:00–19:25 Integrating HER2-Directed Therapies in the Frontline Setting Lung & thoracic cancersBiomarkers & precision oncology |
Instantly find 20 buyers from Vall d'Hebron University Hospital
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction